Resources & Guides

No FDA label or guideline sets one lab schedule for everyone on a GLP-1. Here is what the Wegovy, Ozempic, Zepbound and Mounjaro labels and ADA 2026 actually say about kidney, pancreas, liver, blood sugar, thyroid and nutrition labs, what we suggest on top, and which symptoms need a doctor today.

Complete tirzepatide dosage chart showing Mounjaro and Zepbound titration protocols week-by-week from 2.5mg to 15mg. Includes what to expect at each dose level, side effects by tier, printable download, and a free dosing calculator.

Complete Zepbound (tirzepatide) dosage chart for weight management. Covers the full 2.5 mg to 15 mg titration schedule, SURMOUNT-1 weight loss by dose, KwikPen guide, missed-dose rules, and a Zepbound vs Wegovy comparison.

Retatrutide achieved 24.2% weight loss vs tirzepatide's 20.9%. Compare mechanisms, trial results, side effects, and find out which medication might work better for you.

A tirzepatide constipation guide covering the mechanism, brand-correct FDA label rates for Mounjaro and Zepbound, relief strategies, and when constipation becomes an emergency.

Everything you need to know about tirzepatide dosing: dual-agonist mechanism, clinical trial efficacy data, starting dose through maintenance, titration schedules, half-life pharmacokinetics, side effects, and dosing calculator.

Zepbound side effects guide: nausea 25-29%, diarrhea 19-23%, symptom timeline, serious warnings, and practical management tips for weight loss patients.

Tirzepatide side effects guide: nausea, diarrhea, and other GI symptoms from clinical trial data, plus practical management tips.

Complete guide to tirzepatide weight loss: SURMOUNT trial results showed 20.9% average weight loss at 72 weeks on 15mg dose. How it works, what to expect, timeline, dosing, comparison with Ozempic/Wegovy, and managing side effects.

A neutral look at Ro's GLP-1 program: the current branded-only medication lineup, the two-part membership and medication cost structure, and the alternatives.

Tirzepatide is FDA-approved as Mounjaro and Zepbound, so you might assume alcohol has been studied. It has not. The prescribing information never addresses drinking at all. Here is what the label does say, and what that leaves you to reason about yourself.

With commercial coverage of the Zepbound single-dose pen and the savings card, eligible patients pay as little as $25 per fill, with savings capped at $1,300 per calendar year on that tier. Medicare beneficiaries have a new route from July 1, 2026: the CMS GLP-1 Bridge, which covers the Zepbound KwikPen only at $50 a month. This guide covers the insured path, prior authorization, and appeals.

There is no FDA-approved tirzepatide pill, and the reason is structural rather than a matter of timing. Tirzepatide is a peptide that stomach acid and digestive enzymes break down before it can be absorbed, which is why Mounjaro and Zepbound remain once-weekly injections. This guide covers why, what the approved oral GLP-1 pills actually are, and why orforglipron (Foundayo) is a different molecule rather than tirzepatide in tablet form.

The multi-dose Zepbound KwikPen delivers four weekly tirzepatide doses from one disposable pen. This guide covers priming, dosing, storage, needles, disposal, and how the KwikPen differs from Zepbound's single-dose pen and vial.

Complete guide to reconstituting compounded tirzepatide. Free calculator for BAC water volumes and insulin units, concentration charts for 5mg to 60mg vials, and expert storage tips.

One chart, all the numbers that matter. Zepbound (tirzepatide) and Wegovy (semaglutide) compared row by row using SURMOUNT-5 head-to-head data, dosing ladders, cost, and FDA approvals.

The dose-stratified Zepbound weight loss results from SURMOUNT-1 (5mg, 10mg, 15mg arms) with per-dose responder rates, plus SURMOUNT-2 (T2D), SURMOUNT-4 (maintenance), and SURMOUNT-5 (vs Wegovy) context. Brand-specific Zepbound evidence, FDA-label population.

The patient-journey view of the Zepbound dosing schedule. Maps weeks 1 through 21+ across four phases, with maintenance decision criteria, missed-dose rules, and day-change guidance grounded in the FDA prescribing information.

Tirzepatide is FDA-approved under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea. Compounded tirzepatide is a different story. Here is the full approval timeline, brand-by-brand indications, eligibility, and the compounded vs brand distinction.

Tirzepatide has two FDA-approved brand names, both from Eli Lilly: Mounjaro for type 2 diabetes (May 2022, NDA 215866) and Zepbound for chronic weight management (November 2023, NDA 217806). Same molecule, two indications, two boxes.

The Zepbound KwikPen list price is $1,086.37 a month without insurance. The LillyDirect Self Pay Journey Program (launched February 2026) brings cash-pay vials down to $299 for 2.5mg, $399 for 5mg, and a flat $449 for every dose from 7.5mg to 15mg. This guide covers Zepbound pricing only, with no Mounjaro overlap.

Everything you need to know about ordering Zepbound through LillyDirect: pricing by dose tier, eligibility, pharmacy partners, and the 5-step ordering process.

Tirzepatide-associated hair shedding is real but almost always temporary telogen effluvium triggered by rapid weight loss. This guide covers mechanism, risk factors, prevention, and the 6-12 month recovery timeline.

Compounded tirzepatide costs a fraction of Mounjaro or Zepbound — see our full <a href="/resources/tirzepatide-cost" style="color: #2563eb;">tirzepatide cost guide</a> but sits at the center of an ongoing legal battle between Eli Lilly, compounding pharmacies, and the FDA. This guide covers the regulatory landscape after the October 2024 shortage removal, how to source safely, dosing considerations, reconstitution, storage, and what the court rulings mean for availability.

Mounjaro and Zepbound contain identical tirzepatide (LY3298176). The differences are indication, device, and insurance: not the molecule. Full comparison with cost data and decision framework.

Zepbound is FDA-approved for subcutaneous injection in three sites: abdomen, thigh, and back of upper arm. This guide covers each site, how to rotate with every weekly dose, what skin to avoid, and how to track your schedule.

Zepbound and Ozempic are approved for different conditions. Zepbound targets weight management; Ozempic targets type 2 diabetes. Compare tirzepatide vs semaglutide across mechanisms, trial results, dosing, and cost.

SURMOUNT-5 compared tirzepatide and semaglutide head-to-head for the first time. See the weight loss numbers, mechanism differences, dosing schedules, and which drug may fit your situation.

Zepbound contains tirzepatide, a dual agonist that activates both GLP-1 and GIP receptors simultaneously. Here is exactly what happens in your body, what SURMOUNT-1 showed at 72 weeks, and why the 5-day half-life matters for your dose schedule.

Free tirzepatide dosing calculator plus complete guide. Visualize Mounjaro/Zepbound drug levels, plan titration schedules, understand half-life pharmacokinetics, and manage side effects.

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved as Mounjaro (type 2 diabetes) and Zepbound (weight loss, sleep apnea). Clinical trials show up to 20.9% weight loss. This guide explains the science clearly.

Tirzepatide activates two hormone receptors — GLP-1 and GIP — producing greater fat loss than GLP-1-only drugs. Here's what each receptor does, why the mechanism isn't fully understood, and what the clinical trials show.

Tirzepatide achieved 20.9% weight loss vs semaglutide's 14.9% in clinical trials. The SURPASS-2 head-to-head trial showed tirzepatide superior on both A1C and weight. Compare mechanisms, side effects, dosing, costs, and which GLP-1 medication fits your situation.

While tirzepatide is designed for weekly dosing, emerging interest in microdosing raises questions about splitting doses to optimize tolerability and efficacy. We examine the science, community experiences, and critical considerations.